Rettew Andrew, Garrahy Ian, Rahimian Shoja, Brown Rebecca, Sangha Navdeep
Tower Health System, Reading Hospital, West Reading, PA 19611, USA.
Life (Basel). 2024 Jul 29;14(8):953. doi: 10.3390/life14080953.
Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as "long COVID". Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed.
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的呼吸道病毒感染。尽管它是一种原发性呼吸系统疾病，但通常会因血管系统的全身受累而并发动脉和静脉血栓形成。在这篇综述中，我们将聚焦于COVID-19与血栓形成之间的关联。我们将重点介绍COVID-19凝血病的病理生理学。将讨论COVID-19血管病变的临床表现，重点是静脉和动脉血栓栓塞事件。在COVID-19血管病变和弥散性血管内凝血（DIC）之间进行区分，以及存在争议的领域，如“长新冠”。最后，将讨论目前关于预防和治疗与SARS-CoV-2感染相关血栓形成的专业指南。
